The Schall Law Firm Invites Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc's Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Stockholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Impacted Stockholders Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Impacted Stockholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Actinium Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investors To Join A Securities Fraud Inquiry Into Actinium Pharmaceuticals Inc
LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
